World Investment Advisors Buys 13,022 Shares of Zoetis Inc. $ZTS

World Investment Advisors boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 43.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 42,736 shares of the company’s stock after buying an additional 13,022 shares during the period. World Investment Advisors’ holdings in Zoetis were worth $5,052,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Zoetis by 180.4% during the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares during the period. Empowered Funds LLC grew its holdings in Zoetis by 6.2% during the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC raised its position in Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the period. Sivia Capital Partners LLC lifted its stake in Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Glenview Trust co lifted its stake in Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Activity

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by corporate insiders.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Analysts Set New Price Targets

A number of research firms have recently commented on ZTS. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. UBS Group decreased their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Citigroup dropped their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $126.92.

Zoetis Trading Down 0.1%

Shares of NYSE ZTS opened at $74.73 on Monday. Zoetis Inc. has a twelve month low of $71.47 and a twelve month high of $161.77. The firm has a market cap of $31.33 billion, a PE ratio of 12.39, a price-to-earnings-growth ratio of 1.17 and a beta of 0.75. The business has a fifty day simple moving average of $84.04 and a two-hundred day simple moving average of $109.31. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.